Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.50 |
| ▸ | KDM1A | O60341 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | F9 | P00740 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31501865 | 1.00 | APP (0.51) | APPLTA4HMAPK14L3MBTL1KDM1A | |
| SCHEMBL8924134 | 0.86 | APP (0.51) | APPLTA4HMAPK14L3MBTL1KDM1A | |
| SCHEMBL8298067 | 0.82 | MAOB (0.56) | APPLTA4HMAPK14L3MBTL1MAPT | |
| SCHEMBL3315005 | 0.82 | HTR1A (0.51) | LTA4HMAPK14HTR1ADRD2F9 | |
| SCHEMBL21685531 | 0.81 | KDM1A (0.52) | APPLTA4HMAPK14L3MBTL1KDM1A | |
| SCHEMBL21835559 | 0.81 | MAOB (0.59) | APPL3MBTL1MAPTLMNAMAOB | |
| SCHEMBL292275 | 0.81 | APP (0.72) | APPLTA4HMAPK14L3MBTL1MAPT | |
| SCHEMBL8059557 | 0.81 | LMNA (0.52) | APPLTA4HMAPK14L3MBTL1MAPT | |
| SCHEMBL3920530 | 0.81 | LTA4H (0.49) | APPLTA4HMAPK14L3MBTL1KDM1A | |
| SCHEMBL4053551 | 0.81 | MAOB (0.59) | APPLTA4HMAPK14L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| WO-2023230612-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230612-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-3013805-B1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES AND THEIR USE AS MNK1 AND/OR MNK2 KINASE INHIBITORS | EVOTEC INT GMBH (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-9708274-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATIONAL GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9708274-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATIONAL GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| EP-2687507-B1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2687507-B1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| CN-101421256-A | Thiadiazolidinone inhibitors of ptpase | NOVARTIS AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-5874382-A | Cyclic sulfonamide herbicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| US-5750471-A | PREEMERGENCE, POSTEMERGENCE HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| US-5639906-A | Fluorescent and NMR sensitive pH indicators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0765324-A1 | CYCLIC SULFONAMIDE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995033746-A1 | CYCLIC SULFONAMIDE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI1, PADI6 | APP 2478/4885LTA4H 1776/4885MAPK14 1875/4885 |
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | APP 3032/4885LTA4H 1254/4885MAPK14 909/4885 |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | NEK5, NEK2, SIK2 | APP 4684/4885LTA4H 3615/4885MAPK14 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.